Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Chemed Corp has a consensus price target of $658.5 based on the ratings of 2 analysts. The high is $667 issued by RBC Capital on March 14, 2025. The low is $650 issued by Oppenheimer on February 29, 2024. The 3 most-recent analyst ratings were released by RBC Capital on March 14, 2025, November 5, 2024, and May 21, 2024, respectively. With an average price target of $665.67 between RBC Capital, there's an implied 9.32% upside for Chemed Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/14/2025 | Buy Now | 9.54% | RBC Capital | Ben Hendrix59% | $633 → $667 | Maintains | Outperform | Get Alert |
11/05/2024 | Buy Now | 3.96% | RBC Capital | Ben Hendrix59% | $697 → $633 | Maintains | Outperform | Get Alert |
05/21/2024 | Buy Now | 14.47% | RBC Capital | Ben Hendrix59% | $712 → $697 | Maintains | Outperform | Get Alert |
03/04/2024 | Buy Now | 16.93% | RBC Capital | Ben Hendrix59% | $604 → $712 | Maintains | Outperform | Get Alert |
02/29/2024 | Buy Now | 6.75% | Oppenheimer | Michael Wiederhorn61% | $625 → $650 | Maintains | Outperform | Get Alert |
01/17/2024 | Buy Now | 2.64% | Oppenheimer | Michael Wiederhorn61% | $590 → $625 | Maintains | Outperform | Get Alert |
10/30/2023 | Buy Now | -0.8% | RBC Capital | Ben Hendrix59% | $576 → $604 | Maintains | Outperform | Get Alert |
07/31/2023 | Buy Now | -5.4% | RBC Capital | Ben Hendrix59% | $610 → $576 | Maintains | Outperform | Get Alert |
07/27/2023 | Buy Now | -3.1% | Oppenheimer | Michael Wiederhorn61% | $610 → $590 | Maintains | Outperform | Get Alert |
05/01/2023 | Buy Now | 0.18% | RBC Capital | Ben Hendrix59% | $587 → $610 | Maintains | Outperform | Get Alert |
04/28/2023 | Buy Now | 0.18% | Oppenheimer | Michael Wiederhorn61% | $580 → $610 | Maintains | Outperform | Get Alert |
02/27/2023 | Buy Now | -3.6% | RBC Capital | Ben Hendrix59% | $545 → $587 | Maintains | Outperform | Get Alert |
11/03/2022 | Buy Now | -10.49% | RBC Capital | Ben Hendrix59% | $541 → $545 | Maintains | Outperform | Get Alert |
08/01/2022 | Buy Now | -11.15% | RBC Capital | Ben Hendrix59% | $592 → $541 | Maintains | Outperform | Get Alert |
04/28/2022 | Buy Now | -2.78% | RBC Capital | Ben Hendrix59% | $579 → $592 | Maintains | Outperform | Get Alert |
The latest price target for Chemed (NYSE:CHE) was reported by RBC Capital on March 14, 2025. The analyst firm set a price target for $667.00 expecting CHE to rise to within 12 months (a possible 9.54% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Chemed (NYSE:CHE) was provided by RBC Capital, and Chemed maintained their outperform rating.
There is no last upgrade for Chemed
There is no last downgrade for Chemed.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemed was filed on March 14, 2025 so you should expect the next rating to be made available sometime around March 14, 2026.
While ratings are subjective and will change, the latest Chemed (CHE) rating was a maintained with a price target of $633.00 to $667.00. The current price Chemed (CHE) is trading at is $608.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.